Advertisement
U.S. markets closed
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,131.53
    +62.43 (+0.16%)
     
  • Nasdaq

    15,996.82
    -44.78 (-0.28%)
     
  • Russell 2000

    2,016.69
    +2.85 (+0.14%)
     
  • Crude Oil

    76.57
    +0.08 (+0.10%)
     
  • Gold

    2,045.80
    -3.60 (-0.18%)
     
  • Silver

    22.98
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0820
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • GBP/USD

    1.2672
    +0.0014 (+0.11%)
     
  • USD/JPY

    150.4200
    -0.0800 (-0.05%)
     
  • Bitcoin USD

    51,804.97
    +293.36 (+0.57%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

Amgen's multiple myeloma drug falls short in late stage study

Sept 27 (Reuters) - Amgen Inc said on Tuesday its cancer drug Kyprolis failed to meet the main goal of a late-stage study against Takeda Pharmaceutical Co Ltd's Velcade for treating newly diagnosed multiple myeloma.

The Phase III study evaluated Kyprolis in combination with chemotherapy drug, melphalan and immunosuppressant prednisone.

The U.S. Food and Drug Administration approved Kyprolis in January when administered in combination with certain other therapies to treat patients with multiple myeloma.

(Reporting by Abinaya Vijayaraghavan in Bengaluru; Editing by Sunil Nair)

Advertisement